High-Affinity Anti-CD3 Antibodies With Better Stability and Solubility
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bispecific antibodies targeting CD3 for cancer treatment face challenges such as low production efficiency, stability issues, poor solubility, aggregation propensity, and short half-life, which hinder their broad commercial application and clinical efficacy.
Innovation Solution
Development of anti-CD3 antibodies with high affinity, specifically designed with optimized complementarity determining regions (CDRs) in the light and heavy chain variable regions, achieving binding affinities of 500 pM or less, which enhance developability profiles and reduce off-target binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional bispecific antibodies are used for cancer treatment, then T cell recruitment and activation can be achieved, but production efficiency is low and expression levels in eukaryotic host cells are poor
Solution Approach 1:
The patent applies parameter changes by optimizing the CDR sequences of the anti-CD3 antibody to achieve high binding affinity (KD of 500 pM or less) while improving expression levels and production efficiency in eukaryotic host cells. The specific amino acid sequences in CDRs are modified to enhance both binding characteristics and manufacturability.
2Stability of the object's composition
If conventional bisspecific antibodies are used, then CD3 targeting can be achieved, but stability during storage is poor and shelf-life is low
Solution Approach 1:
The patent improves stability and shelf-life by optimizing the antibody structure through specific CDR sequences that enhance structural integrity and resistance to aggregation, while maintaining high binding affinity to CD3.
3Reliability
If conventional bispecific antibodies are used, then tumor targeting can be achieved, but solubility is poor and aggregation propensity is high
Solution Approach 1:
The patent addresses solubility and aggregation issues by optimizing the amino acid sequences in the CDR regions, which improves the overall solubility characteristics of the antibody while maintaining its tumor targeting capability through high CD3 affinity.
4Ease of operation
If conventional bisspecific antibodies are used, then T cell activation can be achieved, but circulation half-life is short
Solution Approach 1:
The patent optimizes the antibody structure through specific CDR sequences that enhance circulation half-life in humans, allowing the antibody to remain in circulation longer while maintaining effective T cell activation capability.
Data Source
AI summary
Antibodies and antigen-binding fragments thereof with high affinity for CD3 and desirable developability profiles are provided, as well as methods for their manufacture and use.